Abstract 19P
Background
Triple-negaive breast cancer (TNBC) is a highly aggressive subtype with neoadjuvant options historically limited to chemotherapy until the recent success of the KEYNOTE-522 trial. Although TNBC is well known for being associated with constitutional pathogenic BRCA mutations when compared to other types of breast cancer, the genetic profiles of the patients in the KEYNOTE-522 trial are unknown and no subgroup analysis has assessed a possible relationship with treatment efficacy.
Methods
We analysed consecutive index-case genetic consults of TNBC patients (N = 170) between January 2020 and July 2024 in our oncogenetics department. Only patients with treatment history in our center were included. Tumor characteristics, pCR status and the type of chemotherapy agents used were collected. We compared the pCR and non pCR rates according to the genetic status and survival probability distribution stratified by the presence or not of Pembrolizumab and Carboplatin using Fisher’s exact test and the Kaplan-Meier method. A significance threshold of 5% was applied to all statistical analyses.
Results
A total of 132 patients were identified for the analysis. Significant benefits were observed in patients with pCR in terms of EFS (p = 0.001, HR = 0.07 CI 95% 0.02 – 0.21) and OS (p = 0.012, HR = 0.12 CI 95% 0.03 – 0.50), respectively. When comparing patients treated by a neoadjuvant chemotherapy regimen to those treated by pembrolizumab plus chemotherapy, a significantly higher pCR rate was observed with the latter group (p = 0.01). Regarding the presence of pathogenic variants (PV), the following were identified: BRCA1 (N = 10), BRCA2 (N = 3), PALB 2 (N = 1), PMS2 (N = 1), RAD51C (N = 3) and RAD51D (N = 1). 30 patients carried various variants of unknown significance. Notably, all patients carrying a BRCA PV treated with pembrolizumab achieved pCR but results were not statistically significant (p = 0.14).
Conclusions
To our knowledge this is the first descriptive analysis of the genetic landscape of patients with an indication for neoadjuvant Pembrolizumab. Interestingly, all patients carrying pathogenic variants of BRCA treated with pembrolizumab had pCR although results were not statistically significant compared to patients not presenting BRCA PV.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
54P - Superior antitumor activities of fourth-generation CAR-T cells containing three costimulatory domains targeting GD2-positive tumors
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Presenter: Marta Soria Castellano
Session: Poster Display session
Resources:
Abstract
56P - Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
57P - SENDER™ Directed LNP Delivery of mRNA for In Situ generation of highly potent CAR T Cells
Presenter: Biao Ma
Session: Poster Display session
Resources:
Abstract
58P - Cardiovascular outcomes of novel CAR-T cell therapies: A meta-analysis of incidence, risk factors, and management of cardiotoxicity
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
59P - Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Presenter: Nicolas Mach
Session: Poster Display session
Resources:
Abstract
60P - Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
61P - Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
62P - Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells
Presenter: Sumei Chen
Session: Poster Display session
Resources:
Abstract
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract